nodes	percent_of_prediction	percent_of_DWPC	metapath
Midazolam—CYP3A5—Beclomethasone—psoriasis	0.0719	0.113	CbGbCtD
Midazolam—CYP2B6—Cholecalciferol—psoriasis	0.0419	0.0658	CbGbCtD
Midazolam—CYP3A7—Hydrocortisone—psoriasis	0.0306	0.0481	CbGbCtD
Midazolam—CYP3A7-CYP3A51P—Hydrocortisone—psoriasis	0.0306	0.0481	CbGbCtD
Midazolam—CYP3A7—Cyclosporine—psoriasis	0.0289	0.0454	CbGbCtD
Midazolam—CYP3A7-CYP3A51P—Cyclosporine—psoriasis	0.0289	0.0454	CbGbCtD
Midazolam—CYP3A5—Mycophenolate mofetil—psoriasis	0.0286	0.045	CbGbCtD
Midazolam—CYP3A4—Calcitriol—psoriasis	0.025	0.0392	CbGbCtD
Midazolam—CYP3A5—Hydrocortisone—psoriasis	0.023	0.0361	CbGbCtD
Midazolam—CYP3A5—Cyclosporine—psoriasis	0.0217	0.0341	CbGbCtD
Midazolam—CYP3A4—Methoxsalen—psoriasis	0.0194	0.0305	CbGbCtD
Midazolam—CYP3A7—Dexamethasone—psoriasis	0.019	0.0299	CbGbCtD
Midazolam—CYP3A7-CYP3A51P—Dexamethasone—psoriasis	0.019	0.0299	CbGbCtD
Midazolam—ABCB1—Mycophenolate mofetil—psoriasis	0.0186	0.0293	CbGbCtD
Midazolam—CYP2E1—Dexamethasone—psoriasis	0.0184	0.0289	CbGbCtD
Midazolam—CYP2B6—Dexamethasone—psoriasis	0.0181	0.0285	CbGbCtD
Midazolam—ABCB1—Betamethasone—psoriasis	0.016	0.0251	CbGbCtD
Midazolam—ABCB1—Prednisolone—psoriasis	0.0158	0.0248	CbGbCtD
Midazolam—ABCB1—Hydrocortisone—psoriasis	0.015	0.0235	CbGbCtD
Midazolam—ABCB1—Prednisone—psoriasis	0.0149	0.0234	CbGbCtD
Midazolam—CYP3A5—Dexamethasone—psoriasis	0.0143	0.0224	CbGbCtD
Midazolam—ABCB1—Cyclosporine—psoriasis	0.0141	0.0222	CbGbCtD
Midazolam—CYP3A4—Cholecalciferol—psoriasis	0.0129	0.0202	CbGbCtD
Midazolam—CYP3A4—Mycophenolate mofetil—psoriasis	0.0112	0.0175	CbGbCtD
Midazolam—CYP3A4—Triamcinolone—psoriasis	0.0112	0.0175	CbGbCtD
Midazolam—CYP3A4—Betamethasone—psoriasis	0.00958	0.015	CbGbCtD
Midazolam—CYP3A4—Prednisolone—psoriasis	0.00945	0.0148	CbGbCtD
Midazolam—ABCB1—Dexamethasone—psoriasis	0.0093	0.0146	CbGbCtD
Midazolam—CYP3A4—Hydrocortisone—psoriasis	0.00896	0.0141	CbGbCtD
Midazolam—CYP3A4—Prednisone—psoriasis	0.00892	0.014	CbGbCtD
Midazolam—CYP3A4—Cyclosporine—psoriasis	0.00846	0.0133	CbGbCtD
Midazolam—ABCB1—Methotrexate—psoriasis	0.00747	0.0117	CbGbCtD
Midazolam—CYP4B1—Miscellaneous substrates—CYP2S1—psoriasis	0.00739	0.152	CbGpPWpGaD
Midazolam—CYP3A4—Dexamethasone—psoriasis	0.00557	0.00875	CbGbCtD
Midazolam—CYP4B1—Cytochrome P450 - arranged by substrate type—CYP2S1—psoriasis	0.00204	0.0421	CbGpPWpGaD
Midazolam—CYP4B1—Oxidation by Cytochrome P450—CYP2S1—psoriasis	0.00201	0.0415	CbGpPWpGaD
Midazolam—CYP2B6—CYP2E1 reactions—CYP2S1—psoriasis	0.00177	0.0365	CbGpPWpGaD
Midazolam—CYP2E1—CYP2E1 reactions—CYP2S1—psoriasis	0.00173	0.0358	CbGpPWpGaD
Midazolam—CYP4B1—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	0.00165	0.0341	CbGpPWpGaD
Midazolam—CYP3A7—Xenobiotics—CYP2S1—psoriasis	0.00148	0.0306	CbGpPWpGaD
Midazolam—CYP2B6—Xenobiotics—CYP2S1—psoriasis	0.0011	0.0226	CbGpPWpGaD
Midazolam—CYP2E1—Xenobiotics—CYP2S1—psoriasis	0.00107	0.0222	CbGpPWpGaD
Midazolam—CYP3A5—Xenobiotics—CYP2S1—psoriasis	0.00107	0.0221	CbGpPWpGaD
Midazolam—CYP4B1—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—psoriasis	0.000936	0.0193	CbGpPWpGaD
Midazolam—CYP4B1—Biological oxidations—CYP2S1—psoriasis	0.000878	0.0181	CbGpPWpGaD
Midazolam—CYP4B1—Metapathway biotransformation—CYP2S1—psoriasis	0.000866	0.0179	CbGpPWpGaD
Midazolam—CYP4B1—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—psoriasis	0.000653	0.0135	CbGpPWpGaD
Midazolam—ABCB1—Allograft Rejection—IL22—psoriasis	0.000649	0.0134	CbGpPWpGaD
Midazolam—CYP3A7—Cytochrome P450 - arranged by substrate type—CYP2S1—psoriasis	0.000616	0.0127	CbGpPWpGaD
Midazolam—UGT1A4—Aryl Hydrocarbon Receptor Pathway—IL12B—psoriasis	0.000612	0.0126	CbGpPWpGaD
Midazolam—CYP3A7—Oxidation by Cytochrome P450—CYP2S1—psoriasis	0.000608	0.0125	CbGpPWpGaD
Midazolam—UGT1A4—Biological oxidations—CYP2S1—psoriasis	0.000549	0.0113	CbGpPWpGaD
Midazolam—UGT1A4—Metapathway biotransformation—CYP2S1—psoriasis	0.000542	0.0112	CbGpPWpGaD
Midazolam—CYP3A7—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	0.000499	0.0103	CbGpPWpGaD
Midazolam—CYP3A4—Xenobiotics—CYP2S1—psoriasis	0.000498	0.0103	CbGpPWpGaD
Midazolam—CYP2B6—Cytochrome P450 - arranged by substrate type—CYP2S1—psoriasis	0.000455	0.0094	CbGpPWpGaD
Midazolam—CYP2B6—Oxidation by Cytochrome P450—CYP2S1—psoriasis	0.000449	0.00928	CbGpPWpGaD
Midazolam—CYP2E1—Cytochrome P450 - arranged by substrate type—CYP2S1—psoriasis	0.000446	0.00921	CbGpPWpGaD
Midazolam—CYP3A5—Cytochrome P450 - arranged by substrate type—CYP2S1—psoriasis	0.000445	0.00919	CbGpPWpGaD
Midazolam—CYP2E1—Oxidation by Cytochrome P450—CYP2S1—psoriasis	0.00044	0.00909	CbGpPWpGaD
Midazolam—CYP3A5—Oxidation by Cytochrome P450—CYP2S1—psoriasis	0.000439	0.00907	CbGpPWpGaD
Midazolam—GABRQ—Orphan transporters—CARM1—psoriasis	0.00038	0.00785	CbGpPWpGaD
Midazolam—CYP2B6—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	0.000369	0.00762	CbGpPWpGaD
Midazolam—CYP2E1—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	0.000362	0.00747	CbGpPWpGaD
Midazolam—CYP3A5—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	0.000361	0.00745	CbGpPWpGaD
Midazolam—GABRG3—Orphan transporters—CARM1—psoriasis	0.000313	0.00646	CbGpPWpGaD
Midazolam—GABRB1—Orphan transporters—CARM1—psoriasis	0.000308	0.00636	CbGpPWpGaD
Midazolam—UGT1A4—NRF2 pathway—TGFA—psoriasis	0.000306	0.00631	CbGpPWpGaD
Midazolam—GABRA6—Orphan transporters—CARM1—psoriasis	0.000292	0.00602	CbGpPWpGaD
Midazolam—GABRA4—Orphan transporters—CARM1—psoriasis	0.000288	0.00595	CbGpPWpGaD
Midazolam—ABCB1—Drug Induction of Bile Acid Pathway—VDR—psoriasis	0.000269	0.00555	CbGpPWpGaD
Midazolam—CYP3A7—Biological oxidations—CYP2S1—psoriasis	0.000265	0.00547	CbGpPWpGaD
Midazolam—GABRB2—Orphan transporters—CARM1—psoriasis	0.000264	0.00544	CbGpPWpGaD
Midazolam—UGT1A4—Aryl Hydrocarbon Receptor Pathway—IFNG—psoriasis	0.000263	0.00543	CbGpPWpGaD
Midazolam—CYP3A7—Metapathway biotransformation—CYP2S1—psoriasis	0.000262	0.0054	CbGpPWpGaD
Midazolam—GABRA5—Orphan transporters—CARM1—psoriasis	0.000256	0.00528	CbGpPWpGaD
Midazolam—GABRA3—Orphan transporters—CARM1—psoriasis	0.000251	0.00519	CbGpPWpGaD
Midazolam—GABRA2—Orphan transporters—CARM1—psoriasis	0.000247	0.0051	CbGpPWpGaD
Midazolam—GABRB3—Orphan transporters—CARM1—psoriasis	0.000245	0.00507	CbGpPWpGaD
Midazolam—GABRG2—Orphan transporters—CARM1—psoriasis	0.000241	0.00497	CbGpPWpGaD
Midazolam—UGT1A4—Aryl Hydrocarbon Receptor Pathway—JUN—psoriasis	0.000227	0.00469	CbGpPWpGaD
Midazolam—GABRA1—Orphan transporters—CARM1—psoriasis	0.000211	0.00435	CbGpPWpGaD
Midazolam—CYP2B6—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—psoriasis	0.000209	0.00432	CbGpPWpGaD
Midazolam—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP2S1—psoriasis	0.000207	0.00427	CbGpPWpGaD
Midazolam—CYP2E1—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—psoriasis	0.000205	0.00423	CbGpPWpGaD
Midazolam—CYP3A4—Oxidation by Cytochrome P450—CYP2S1—psoriasis	0.000204	0.00422	CbGpPWpGaD
Midazolam—SLC22A1—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—CP—psoriasis	0.0002	0.00412	CbGpPWpGaD
Midazolam—Neuropathy peripheral—Prednisone—psoriasis	0.000199	0.000631	CcSEcCtD
Midazolam—Anxiety—Mycophenolate mofetil—psoriasis	0.000198	0.00063	CcSEcCtD
Midazolam—Unspecified disorder of skin and subcutaneous tissue—Mycophenolate mofetil—psoriasis	0.000197	0.000628	CcSEcCtD
Midazolam—Confusional state—Cyclosporine—psoriasis	0.000197	0.000626	CcSEcCtD
Midazolam—CYP2B6—Biological oxidations—CYP2S1—psoriasis	0.000196	0.00405	CbGpPWpGaD
Midazolam—Vertigo—Prednisolone—psoriasis	0.000196	0.000622	CcSEcCtD
Midazolam—Anaphylactic shock—Cyclosporine—psoriasis	0.000195	0.000621	CcSEcCtD
Midazolam—Syncope—Prednisolone—psoriasis	0.000195	0.000621	CcSEcCtD
Midazolam—Eye disorder—Dexamethasone—psoriasis	0.000195	0.00062	CcSEcCtD
Midazolam—Eye disorder—Betamethasone—psoriasis	0.000195	0.00062	CcSEcCtD
Midazolam—Dry mouth—Mycophenolate mofetil—psoriasis	0.000194	0.000618	CcSEcCtD
Midazolam—CYP2B6—Metapathway biotransformation—CYP2S1—psoriasis	0.000193	0.00399	CbGpPWpGaD
Midazolam—Confusional state—Mycophenolate mofetil—psoriasis	0.000192	0.000611	CcSEcCtD
Midazolam—CYP2E1—Biological oxidations—CYP2S1—psoriasis	0.000192	0.00397	CbGpPWpGaD
Midazolam—CYP3A5—Biological oxidations—CYP2S1—psoriasis	0.000192	0.00396	CbGpPWpGaD
Midazolam—Nervous system disorder—Cyclosporine—psoriasis	0.000192	0.000609	CcSEcCtD
Midazolam—Vertigo—Hydrocortisone—psoriasis	0.000191	0.000608	CcSEcCtD
Midazolam—Syncope—Hydrocortisone—psoriasis	0.000191	0.000606	CcSEcCtD
Midazolam—Dizziness—Hydroxyurea—psoriasis	0.000191	0.000606	CcSEcCtD
Midazolam—Anaphylactic shock—Mycophenolate mofetil—psoriasis	0.000191	0.000606	CcSEcCtD
Midazolam—Skin disorder—Cyclosporine—psoriasis	0.00019	0.000603	CcSEcCtD
Midazolam—CYP2E1—Metapathway biotransformation—CYP2S1—psoriasis	0.000189	0.00391	CbGpPWpGaD
Midazolam—CYP3A5—Metapathway biotransformation—CYP2S1—psoriasis	0.000189	0.0039	CbGpPWpGaD
Midazolam—Shock—Mycophenolate mofetil—psoriasis	0.000188	0.000596	CcSEcCtD
Midazolam—Nervous system disorder—Mycophenolate mofetil—psoriasis	0.000187	0.000594	CcSEcCtD
Midazolam—Tachycardia—Mycophenolate mofetil—psoriasis	0.000186	0.000591	CcSEcCtD
Midazolam—Skin disorder—Mycophenolate mofetil—psoriasis	0.000185	0.000588	CcSEcCtD
Midazolam—Bradycardia—Prednisone—psoriasis	0.000185	0.000588	CcSEcCtD
Midazolam—Vomiting—Hydroxyurea—psoriasis	0.000183	0.000583	CcSEcCtD
Midazolam—Rash—Hydroxyurea—psoriasis	0.000182	0.000578	CcSEcCtD
Midazolam—Erythema—Dexamethasone—psoriasis	0.000182	0.000578	CcSEcCtD
Midazolam—Erythema—Betamethasone—psoriasis	0.000182	0.000578	CcSEcCtD
Midazolam—Dermatitis—Hydroxyurea—psoriasis	0.000182	0.000577	CcSEcCtD
Midazolam—Hallucination—Prednisone—psoriasis	0.000181	0.000575	CcSEcCtD
Midazolam—Headache—Hydroxyurea—psoriasis	0.000181	0.000574	CcSEcCtD
Midazolam—Anxiety—Hydrocortisone—psoriasis	0.000181	0.000574	CcSEcCtD
Midazolam—Vertigo—Triamcinolone—psoriasis	0.00018	0.000572	CcSEcCtD
Midazolam—Unspecified disorder of skin and subcutaneous tissue—Hydrocortisone—psoriasis	0.00018	0.000572	CcSEcCtD
Midazolam—Syncope—Triamcinolone—psoriasis	0.00018	0.000571	CcSEcCtD
Midazolam—GABRA1—SIDS Susceptibility Pathways—RUNX3—psoriasis	0.000179	0.0037	CbGpPWpGaD
Midazolam—Connective tissue disorder—Prednisone—psoriasis	0.000179	0.000568	CcSEcCtD
Midazolam—Hypotension—Mycophenolate mofetil—psoriasis	0.000178	0.000566	CcSEcCtD
Midazolam—Anaphylactic shock—Prednisolone—psoriasis	0.000178	0.000565	CcSEcCtD
Midazolam—CYP4B1—Metabolism—NDUFA5—psoriasis	0.000177	0.00364	CbGpPWpGaD
Midazolam—Paraesthesia—Cyclosporine—psoriasis	0.000175	0.000558	CcSEcCtD
Midazolam—Shock—Prednisolone—psoriasis	0.000175	0.000556	CcSEcCtD
Midazolam—Cough—Triamcinolone—psoriasis	0.000175	0.000556	CcSEcCtD
Midazolam—Dyspnoea—Cyclosporine—psoriasis	0.000174	0.000554	CcSEcCtD
Midazolam—Somnolence—Cyclosporine—psoriasis	0.000174	0.000552	CcSEcCtD
Midazolam—Anaphylactic shock—Hydrocortisone—psoriasis	0.000174	0.000552	CcSEcCtD
Midazolam—Tachycardia—Prednisolone—psoriasis	0.000174	0.000552	CcSEcCtD
Midazolam—Asthenia—Mycophenolic acid—psoriasis	0.000173	0.000551	CcSEcCtD
Midazolam—Dyspepsia—Cyclosporine—psoriasis	0.000172	0.000547	CcSEcCtD
Midazolam—Nausea—Hydroxyurea—psoriasis	0.000171	0.000544	CcSEcCtD
Midazolam—Paraesthesia—Mycophenolate mofetil—psoriasis	0.000171	0.000544	CcSEcCtD
Midazolam—Pruritus—Mycophenolic acid—psoriasis	0.000171	0.000543	CcSEcCtD
Midazolam—Shock—Hydrocortisone—psoriasis	0.000171	0.000543	CcSEcCtD
Midazolam—Nervous system disorder—Hydrocortisone—psoriasis	0.00017	0.000541	CcSEcCtD
Midazolam—UGT1A4—Aryl Hydrocarbon Receptor Pathway—TNF—psoriasis	0.00017	0.00351	CbGpPWpGaD
Midazolam—Eye disorder—Prednisone—psoriasis	0.00017	0.00054	CcSEcCtD
Midazolam—Dyspnoea—Mycophenolate mofetil—psoriasis	0.00017	0.00054	CcSEcCtD
Midazolam—Tachycardia—Hydrocortisone—psoriasis	0.000169	0.000539	CcSEcCtD
Midazolam—Somnolence—Mycophenolate mofetil—psoriasis	0.000169	0.000539	CcSEcCtD
Midazolam—Drowsiness—Methotrexate—psoriasis	0.000169	0.000538	CcSEcCtD
Midazolam—Depression—Methotrexate—psoriasis	0.000169	0.000537	CcSEcCtD
Midazolam—Gastrointestinal disorder—Cyclosporine—psoriasis	0.000169	0.000536	CcSEcCtD
Midazolam—Skin disorder—Hydrocortisone—psoriasis	0.000169	0.000536	CcSEcCtD
Midazolam—Fatigue—Cyclosporine—psoriasis	0.000168	0.000535	CcSEcCtD
Midazolam—Dyspepsia—Mycophenolate mofetil—psoriasis	0.000168	0.000533	CcSEcCtD
Midazolam—CYP3A4—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	0.000168	0.00346	CbGpPWpGaD
Midazolam—Pain—Cyclosporine—psoriasis	0.000167	0.000531	CcSEcCtD
Midazolam—Constipation—Cyclosporine—psoriasis	0.000167	0.000531	CcSEcCtD
Midazolam—Dry mouth—Triamcinolone—psoriasis	0.000167	0.00053	CcSEcCtD
Midazolam—CYP2E1—Tryptophan metabolism—CAT—psoriasis	0.000166	0.00342	CbGpPWpGaD
Midazolam—CYP3A4—Drug Induction of Bile Acid Pathway—VDR—psoriasis	0.000166	0.00342	CbGpPWpGaD
Midazolam—CYP4B1—Metabolism of lipids and lipoproteins—CARM1—psoriasis	0.000165	0.0034	CbGpPWpGaD
Midazolam—Gastrointestinal disorder—Mycophenolate mofetil—psoriasis	0.000165	0.000523	CcSEcCtD
Midazolam—Immune system disorder—Prednisone—psoriasis	0.000164	0.000522	CcSEcCtD
Midazolam—Anaphylactic shock—Triamcinolone—psoriasis	0.000164	0.00052	CcSEcCtD
Midazolam—Vertigo—Betamethasone—psoriasis	0.000163	0.000519	CcSEcCtD
Midazolam—Vertigo—Dexamethasone—psoriasis	0.000163	0.000519	CcSEcCtD
Midazolam—Syncope—Dexamethasone—psoriasis	0.000163	0.000518	CcSEcCtD
Midazolam—Syncope—Betamethasone—psoriasis	0.000163	0.000518	CcSEcCtD
Midazolam—Constipation—Mycophenolate mofetil—psoriasis	0.000163	0.000518	CcSEcCtD
Midazolam—Pain—Mycophenolate mofetil—psoriasis	0.000163	0.000518	CcSEcCtD
Midazolam—Hypotension—Hydrocortisone—psoriasis	0.000162	0.000516	CcSEcCtD
Midazolam—Feeling abnormal—Cyclosporine—psoriasis	0.000161	0.000512	CcSEcCtD
Midazolam—Shock—Triamcinolone—psoriasis	0.000161	0.000511	CcSEcCtD
Midazolam—Dizziness—Mycophenolic acid—psoriasis	0.00016	0.000508	CcSEcCtD
Midazolam—Paraesthesia—Prednisolone—psoriasis	0.00016	0.000507	CcSEcCtD
Midazolam—Tachycardia—Triamcinolone—psoriasis	0.00016	0.000507	CcSEcCtD
Midazolam—ABCB1—HIF-1-alpha transcription factor network—CP—psoriasis	0.000159	0.00329	CbGpPWpGaD
Midazolam—Mental disorder—Prednisone—psoriasis	0.000159	0.000506	CcSEcCtD
Midazolam—Erythema—Prednisone—psoriasis	0.000158	0.000503	CcSEcCtD
Midazolam—Feeling abnormal—Mycophenolate mofetil—psoriasis	0.000157	0.000499	CcSEcCtD
Midazolam—Paraesthesia—Hydrocortisone—psoriasis	0.000156	0.000496	CcSEcCtD
Midazolam—Urticaria—Cyclosporine—psoriasis	0.000155	0.000493	CcSEcCtD
Midazolam—ABCB1—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—psoriasis	0.000154	0.00319	CbGpPWpGaD
Midazolam—Anxiety—Betamethasone—psoriasis	0.000154	0.00049	CcSEcCtD
Midazolam—Anxiety—Dexamethasone—psoriasis	0.000154	0.00049	CcSEcCtD
Midazolam—Vomiting—Mycophenolic acid—psoriasis	0.000154	0.000488	CcSEcCtD
Midazolam—Dyspepsia—Hydrocortisone—psoriasis	0.000153	0.000486	CcSEcCtD
Midazolam—Rash—Mycophenolic acid—psoriasis	0.000152	0.000484	CcSEcCtD
Midazolam—Dermatitis—Mycophenolic acid—psoriasis	0.000152	0.000484	CcSEcCtD
Midazolam—Pain—Prednisolone—psoriasis	0.000152	0.000483	CcSEcCtD
Midazolam—Urticaria—Mycophenolate mofetil—psoriasis	0.000151	0.000481	CcSEcCtD
Midazolam—Headache—Mycophenolic acid—psoriasis	0.000151	0.000481	CcSEcCtD
Midazolam—CYP4B1—Metabolism—CYP2S1—psoriasis	0.00015	0.0031	CbGpPWpGaD
Midazolam—Gastrointestinal disorder—Hydrocortisone—psoriasis	0.00015	0.000476	CcSEcCtD
Midazolam—Fatigue—Hydrocortisone—psoriasis	0.00015	0.000476	CcSEcCtD
Midazolam—Vision blurred—Prednisone—psoriasis	0.000149	0.000474	CcSEcCtD
Midazolam—Pain—Hydrocortisone—psoriasis	0.000149	0.000472	CcSEcCtD
Midazolam—Anaphylactic shock—Dexamethasone—psoriasis	0.000148	0.000472	CcSEcCtD
Midazolam—Anaphylactic shock—Betamethasone—psoriasis	0.000148	0.000472	CcSEcCtD
Midazolam—Paraesthesia—Triamcinolone—psoriasis	0.000147	0.000467	CcSEcCtD
Midazolam—Feeling abnormal—Prednisolone—psoriasis	0.000147	0.000466	CcSEcCtD
Midazolam—Visual impairment—Methotrexate—psoriasis	0.000146	0.000465	CcSEcCtD
Midazolam—Shock—Dexamethasone—psoriasis	0.000146	0.000464	CcSEcCtD
Midazolam—Shock—Betamethasone—psoriasis	0.000146	0.000464	CcSEcCtD
Midazolam—CYP2B6—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—psoriasis	0.000146	0.00301	CbGpPWpGaD
Midazolam—Dyspnoea—Triamcinolone—psoriasis	0.000146	0.000463	CcSEcCtD
Midazolam—Nervous system disorder—Dexamethasone—psoriasis	0.000146	0.000462	CcSEcCtD
Midazolam—Nervous system disorder—Betamethasone—psoriasis	0.000146	0.000462	CcSEcCtD
Midazolam—Agitation—Prednisone—psoriasis	0.000146	0.000462	CcSEcCtD
Midazolam—Tachycardia—Dexamethasone—psoriasis	0.000145	0.00046	CcSEcCtD
Midazolam—Tachycardia—Betamethasone—psoriasis	0.000145	0.00046	CcSEcCtD
Midazolam—Hypersensitivity—Cyclosporine—psoriasis	0.000144	0.000458	CcSEcCtD
Midazolam—Dyspepsia—Triamcinolone—psoriasis	0.000144	0.000457	CcSEcCtD
Midazolam—Nausea—Mycophenolic acid—psoriasis	0.000143	0.000456	CcSEcCtD
Midazolam—Feeling abnormal—Hydrocortisone—psoriasis	0.000143	0.000455	CcSEcCtD
Midazolam—CYP2E1—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—psoriasis	0.000143	0.00295	CbGpPWpGaD
Midazolam—Vertigo—Prednisone—psoriasis	0.000142	0.000452	CcSEcCtD
Midazolam—Eye disorder—Methotrexate—psoriasis	0.000142	0.000451	CcSEcCtD
Midazolam—Syncope—Prednisone—psoriasis	0.000142	0.000451	CcSEcCtD
Midazolam—GABRA1—SIDS Susceptibility Pathways—IL13—psoriasis	0.000141	0.00292	CbGpPWpGaD
Midazolam—Urticaria—Prednisolone—psoriasis	0.000141	0.000449	CcSEcCtD
Midazolam—Cardiac disorder—Methotrexate—psoriasis	0.000141	0.000448	CcSEcCtD
Midazolam—Fatigue—Triamcinolone—psoriasis	0.000141	0.000448	CcSEcCtD
Midazolam—Hypersensitivity—Mycophenolate mofetil—psoriasis	0.00014	0.000446	CcSEcCtD
Midazolam—Asthenia—Cyclosporine—psoriasis	0.00014	0.000446	CcSEcCtD
Midazolam—Pain—Triamcinolone—psoriasis	0.00014	0.000444	CcSEcCtD
Midazolam—Hypotension—Dexamethasone—psoriasis	0.000139	0.000441	CcSEcCtD
Midazolam—Hypotension—Betamethasone—psoriasis	0.000139	0.000441	CcSEcCtD
Midazolam—Pruritus—Cyclosporine—psoriasis	0.000138	0.000439	CcSEcCtD
Midazolam—Urticaria—Hydrocortisone—psoriasis	0.000138	0.000438	CcSEcCtD
Midazolam—Immune system disorder—Methotrexate—psoriasis	0.000137	0.000436	CcSEcCtD
Midazolam—Mediastinal disorder—Methotrexate—psoriasis	0.000137	0.000435	CcSEcCtD
Midazolam—Asthenia—Mycophenolate mofetil—psoriasis	0.000137	0.000435	CcSEcCtD
Midazolam—Chills—Methotrexate—psoriasis	0.000136	0.000433	CcSEcCtD
Midazolam—Pruritus—Mycophenolate mofetil—psoriasis	0.000135	0.000429	CcSEcCtD
Midazolam—Feeling abnormal—Triamcinolone—psoriasis	0.000135	0.000428	CcSEcCtD
Midazolam—Anxiety—Prednisone—psoriasis	0.000134	0.000427	CcSEcCtD
Midazolam—Unspecified disorder of skin and subcutaneous tissue—Prednisone—psoriasis	0.000134	0.000425	CcSEcCtD
Midazolam—Paraesthesia—Betamethasone—psoriasis	0.000133	0.000423	CcSEcCtD
Midazolam—Paraesthesia—Dexamethasone—psoriasis	0.000133	0.000423	CcSEcCtD
Midazolam—Mental disorder—Methotrexate—psoriasis	0.000133	0.000423	CcSEcCtD
Midazolam—Erythema—Methotrexate—psoriasis	0.000132	0.00042	CcSEcCtD
Midazolam—Hypersensitivity—Prednisolone—psoriasis	0.000131	0.000416	CcSEcCtD
Midazolam—Dyspepsia—Dexamethasone—psoriasis	0.000131	0.000415	CcSEcCtD
Midazolam—Dyspepsia—Betamethasone—psoriasis	0.000131	0.000415	CcSEcCtD
Midazolam—Urticaria—Triamcinolone—psoriasis	0.00013	0.000413	CcSEcCtD
Midazolam—Dizziness—Cyclosporine—psoriasis	0.000129	0.000411	CcSEcCtD
Midazolam—Anaphylactic shock—Prednisone—psoriasis	0.000129	0.000411	CcSEcCtD
Midazolam—Gastrointestinal disorder—Dexamethasone—psoriasis	0.000128	0.000407	CcSEcCtD
Midazolam—Gastrointestinal disorder—Betamethasone—psoriasis	0.000128	0.000407	CcSEcCtD
Midazolam—Hypersensitivity—Hydrocortisone—psoriasis	0.000128	0.000407	CcSEcCtD
Midazolam—Fatigue—Dexamethasone—psoriasis	0.000128	0.000407	CcSEcCtD
Midazolam—Fatigue—Betamethasone—psoriasis	0.000128	0.000407	CcSEcCtD
Midazolam—Shock—Prednisone—psoriasis	0.000127	0.000404	CcSEcCtD
Midazolam—Pain—Dexamethasone—psoriasis	0.000127	0.000403	CcSEcCtD
Midazolam—Pain—Betamethasone—psoriasis	0.000127	0.000403	CcSEcCtD
Midazolam—Nervous system disorder—Prednisone—psoriasis	0.000127	0.000403	CcSEcCtD
Midazolam—Tachycardia—Prednisone—psoriasis	0.000126	0.000401	CcSEcCtD
Midazolam—Dizziness—Mycophenolate mofetil—psoriasis	0.000126	0.000401	CcSEcCtD
Midazolam—Skin disorder—Prednisone—psoriasis	0.000126	0.000399	CcSEcCtD
Midazolam—Vision blurred—Methotrexate—psoriasis	0.000125	0.000396	CcSEcCtD
Midazolam—Asthenia—Hydrocortisone—psoriasis	0.000125	0.000396	CcSEcCtD
Midazolam—Vomiting—Cyclosporine—psoriasis	0.000124	0.000395	CcSEcCtD
Midazolam—Rash—Cyclosporine—psoriasis	0.000123	0.000392	CcSEcCtD
Midazolam—Dermatitis—Cyclosporine—psoriasis	0.000123	0.000391	CcSEcCtD
Midazolam—ABCB1—Allograft Rejection—HLA-C—psoriasis	0.000123	0.00254	CbGpPWpGaD
Midazolam—Pruritus—Hydrocortisone—psoriasis	0.000123	0.00039	CcSEcCtD
Midazolam—Headache—Cyclosporine—psoriasis	0.000122	0.000389	CcSEcCtD
Midazolam—Feeling abnormal—Dexamethasone—psoriasis	0.000122	0.000389	CcSEcCtD
Midazolam—Feeling abnormal—Betamethasone—psoriasis	0.000122	0.000389	CcSEcCtD
Midazolam—ABCB1—Allograft Rejection—IL13—psoriasis	0.000122	0.00252	CbGpPWpGaD
Midazolam—Vomiting—Mycophenolate mofetil—psoriasis	0.000121	0.000385	CcSEcCtD
Midazolam—Hypersensitivity—Triamcinolone—psoriasis	0.00012	0.000383	CcSEcCtD
Midazolam—Rash—Mycophenolate mofetil—psoriasis	0.00012	0.000382	CcSEcCtD
Midazolam—Dermatitis—Mycophenolate mofetil—psoriasis	0.00012	0.000382	CcSEcCtD
Midazolam—Headache—Mycophenolate mofetil—psoriasis	0.000119	0.000379	CcSEcCtD
Midazolam—Vertigo—Methotrexate—psoriasis	0.000119	0.000378	CcSEcCtD
Midazolam—Urticaria—Betamethasone—psoriasis	0.000118	0.000375	CcSEcCtD
Midazolam—Urticaria—Dexamethasone—psoriasis	0.000118	0.000375	CcSEcCtD
Midazolam—Dizziness—Prednisolone—psoriasis	0.000118	0.000374	CcSEcCtD
Midazolam—Asthenia—Triamcinolone—psoriasis	0.000117	0.000373	CcSEcCtD
Midazolam—Nausea—Cyclosporine—psoriasis	0.000116	0.000369	CcSEcCtD
Midazolam—Paraesthesia—Prednisone—psoriasis	0.000116	0.000369	CcSEcCtD
Midazolam—Pruritus—Triamcinolone—psoriasis	0.000116	0.000368	CcSEcCtD
Midazolam—Cough—Methotrexate—psoriasis	0.000115	0.000367	CcSEcCtD
Midazolam—Dizziness—Hydrocortisone—psoriasis	0.000115	0.000365	CcSEcCtD
Midazolam—Dyspepsia—Prednisone—psoriasis	0.000114	0.000361	CcSEcCtD
Midazolam—Nausea—Mycophenolate mofetil—psoriasis	0.000113	0.00036	CcSEcCtD
Midazolam—ABCB1—Allograft Rejection—IL17A—psoriasis	0.000112	0.00232	CbGpPWpGaD
Midazolam—Rash—Prednisolone—psoriasis	0.000112	0.000356	CcSEcCtD
Midazolam—Dermatitis—Prednisolone—psoriasis	0.000112	0.000356	CcSEcCtD
Midazolam—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—psoriasis	0.000112	0.000356	CcSEcCtD
Midazolam—Fatigue—Prednisone—psoriasis	0.000111	0.000354	CcSEcCtD
Midazolam—Headache—Prednisolone—psoriasis	0.000111	0.000354	CcSEcCtD
Midazolam—Constipation—Prednisone—psoriasis	0.000111	0.000351	CcSEcCtD
Midazolam—UGT1A4—Metabolism—NDUFA5—psoriasis	0.00011	0.00228	CbGpPWpGaD
Midazolam—Vomiting—Hydrocortisone—psoriasis	0.00011	0.000351	CcSEcCtD
Midazolam—Rash—Hydrocortisone—psoriasis	0.00011	0.000348	CcSEcCtD
Midazolam—Dermatitis—Hydrocortisone—psoriasis	0.000109	0.000348	CcSEcCtD
Midazolam—Confusional state—Methotrexate—psoriasis	0.000109	0.000346	CcSEcCtD
Midazolam—Headache—Hydrocortisone—psoriasis	0.000109	0.000346	CcSEcCtD
Midazolam—Dizziness—Triamcinolone—psoriasis	0.000108	0.000344	CcSEcCtD
Midazolam—Anaphylactic shock—Methotrexate—psoriasis	0.000108	0.000343	CcSEcCtD
Midazolam—ABCB1—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—psoriasis	0.000108	0.00222	CbGpPWpGaD
Midazolam—Feeling abnormal—Prednisone—psoriasis	0.000106	0.000338	CcSEcCtD
Midazolam—Asthenia—Betamethasone—psoriasis	0.000106	0.000338	CcSEcCtD
Midazolam—Asthenia—Dexamethasone—psoriasis	0.000106	0.000338	CcSEcCtD
Midazolam—Nervous system disorder—Methotrexate—psoriasis	0.000106	0.000337	CcSEcCtD
Midazolam—Nausea—Prednisolone—psoriasis	0.000106	0.000336	CcSEcCtD
Midazolam—Pruritus—Betamethasone—psoriasis	0.000105	0.000334	CcSEcCtD
Midazolam—Pruritus—Dexamethasone—psoriasis	0.000105	0.000334	CcSEcCtD
Midazolam—Skin disorder—Methotrexate—psoriasis	0.000105	0.000333	CcSEcCtD
Midazolam—ABCB1—Allograft Rejection—IL12B—psoriasis	0.000105	0.00216	CbGpPWpGaD
Midazolam—Vomiting—Triamcinolone—psoriasis	0.000104	0.00033	CcSEcCtD
Midazolam—Nausea—Hydrocortisone—psoriasis	0.000103	0.000328	CcSEcCtD
Midazolam—Rash—Triamcinolone—psoriasis	0.000103	0.000328	CcSEcCtD
Midazolam—Dermatitis—Triamcinolone—psoriasis	0.000103	0.000327	CcSEcCtD
Midazolam—Urticaria—Prednisone—psoriasis	0.000103	0.000326	CcSEcCtD
Midazolam—Headache—Triamcinolone—psoriasis	0.000102	0.000326	CcSEcCtD
Midazolam—ABCB1—Allograft Rejection—HLA-E—psoriasis	0.000102	0.00211	CbGpPWpGaD
Midazolam—GABRR1—Transmembrane transport of small molecules—CP—psoriasis	0.000102	0.00211	CbGpPWpGaD
Midazolam—Hypotension—Methotrexate—psoriasis	0.000101	0.000321	CcSEcCtD
Midazolam—Dizziness—Dexamethasone—psoriasis	9.81e-05	0.000312	CcSEcCtD
Midazolam—Dizziness—Betamethasone—psoriasis	9.81e-05	0.000312	CcSEcCtD
Midazolam—GABRR2—Transmembrane transport of small molecules—CP—psoriasis	9.73e-05	0.00201	CbGpPWpGaD
Midazolam—GABRQ—Transmembrane transport of small molecules—CP—psoriasis	9.73e-05	0.00201	CbGpPWpGaD
Midazolam—GABRR1—Transmembrane transport of small molecules—CARM1—psoriasis	9.73e-05	0.00201	CbGpPWpGaD
Midazolam—Nausea—Triamcinolone—psoriasis	9.71e-05	0.000309	CcSEcCtD
Midazolam—Paraesthesia—Methotrexate—psoriasis	9.7e-05	0.000308	CcSEcCtD
Midazolam—Dyspnoea—Methotrexate—psoriasis	9.63e-05	0.000306	CcSEcCtD
Midazolam—Somnolence—Methotrexate—psoriasis	9.6e-05	0.000305	CcSEcCtD
Midazolam—Hypersensitivity—Prednisone—psoriasis	9.52e-05	0.000303	CcSEcCtD
Midazolam—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—psoriasis	9.51e-05	0.00196	CbGpPWpGaD
Midazolam—Dyspepsia—Methotrexate—psoriasis	9.51e-05	0.000302	CcSEcCtD
Midazolam—Vomiting—Dexamethasone—psoriasis	9.43e-05	0.0003	CcSEcCtD
Midazolam—Vomiting—Betamethasone—psoriasis	9.43e-05	0.0003	CcSEcCtD
Midazolam—UGT1A4—Metabolism—CYP2S1—psoriasis	9.39e-05	0.00194	CbGpPWpGaD
Midazolam—Rash—Betamethasone—psoriasis	9.36e-05	0.000297	CcSEcCtD
Midazolam—Rash—Dexamethasone—psoriasis	9.36e-05	0.000297	CcSEcCtD
Midazolam—Dermatitis—Betamethasone—psoriasis	9.35e-05	0.000297	CcSEcCtD
Midazolam—Dermatitis—Dexamethasone—psoriasis	9.35e-05	0.000297	CcSEcCtD
Midazolam—Gastrointestinal disorder—Methotrexate—psoriasis	9.32e-05	0.000296	CcSEcCtD
Midazolam—Fatigue—Methotrexate—psoriasis	9.31e-05	0.000296	CcSEcCtD
Midazolam—Headache—Betamethasone—psoriasis	9.3e-05	0.000295	CcSEcCtD
Midazolam—Headache—Dexamethasone—psoriasis	9.3e-05	0.000295	CcSEcCtD
Midazolam—GABRQ—Transmembrane transport of small molecules—CARM1—psoriasis	9.28e-05	0.00192	CbGpPWpGaD
Midazolam—GABRR2—Transmembrane transport of small molecules—CARM1—psoriasis	9.28e-05	0.00192	CbGpPWpGaD
Midazolam—Asthenia—Prednisone—psoriasis	9.27e-05	0.000295	CcSEcCtD
Midazolam—Pain—Methotrexate—psoriasis	9.23e-05	0.000293	CcSEcCtD
Midazolam—Pruritus—Prednisone—psoriasis	9.14e-05	0.000291	CcSEcCtD
Midazolam—SLC22A1—SLC-mediated transmembrane transport—CP—psoriasis	9.08e-05	0.00187	CbGpPWpGaD
Midazolam—CYP3A4—Biological oxidations—CYP2S1—psoriasis	8.91e-05	0.00184	CbGpPWpGaD
Midazolam—Feeling abnormal—Methotrexate—psoriasis	8.9e-05	0.000283	CcSEcCtD
Midazolam—GABRA1—SIDS Susceptibility Pathways—IL10—psoriasis	8.85e-05	0.00183	CbGpPWpGaD
Midazolam—Nausea—Dexamethasone—psoriasis	8.81e-05	0.00028	CcSEcCtD
Midazolam—Nausea—Betamethasone—psoriasis	8.81e-05	0.00028	CcSEcCtD
Midazolam—CYP3A4—Metapathway biotransformation—CYP2S1—psoriasis	8.79e-05	0.00181	CbGpPWpGaD
Midazolam—Urticaria—Methotrexate—psoriasis	8.58e-05	0.000273	CcSEcCtD
Midazolam—Dizziness—Prednisone—psoriasis	8.54e-05	0.000272	CcSEcCtD
Midazolam—ABCB1—Integrated Pancreatic Cancer Pathway—PTTG1—psoriasis	8.45e-05	0.00174	CbGpPWpGaD
Midazolam—GABRB3—BDNF signaling pathway—NFKBIA—psoriasis	8.42e-05	0.00174	CbGpPWpGaD
Midazolam—Vomiting—Prednisone—psoriasis	8.22e-05	0.000261	CcSEcCtD
Midazolam—Rash—Prednisone—psoriasis	8.15e-05	0.000259	CcSEcCtD
Midazolam—Dermatitis—Prednisone—psoriasis	8.14e-05	0.000259	CcSEcCtD
Midazolam—Headache—Prednisone—psoriasis	8.1e-05	0.000257	CcSEcCtD
Midazolam—GABRG3—Transmembrane transport of small molecules—CP—psoriasis	8.01e-05	0.00165	CbGpPWpGaD
Midazolam—Hypersensitivity—Methotrexate—psoriasis	7.96e-05	0.000253	CcSEcCtD
Midazolam—GABRB1—Transmembrane transport of small molecules—CP—psoriasis	7.89e-05	0.00163	CbGpPWpGaD
Midazolam—CYP4B1—Metabolism of lipids and lipoproteins—APOE—psoriasis	7.87e-05	0.00162	CbGpPWpGaD
Midazolam—Asthenia—Methotrexate—psoriasis	7.75e-05	0.000246	CcSEcCtD
Midazolam—CYP3A4—Tryptophan metabolism—CAT—psoriasis	7.69e-05	0.00159	CbGpPWpGaD
Midazolam—Nausea—Prednisone—psoriasis	7.68e-05	0.000244	CcSEcCtD
Midazolam—ABCB1—Allograft Rejection—IL10—psoriasis	7.65e-05	0.00158	CbGpPWpGaD
Midazolam—GABRG3—Transmembrane transport of small molecules—CARM1—psoriasis	7.64e-05	0.00158	CbGpPWpGaD
Midazolam—Pruritus—Methotrexate—psoriasis	7.64e-05	0.000243	CcSEcCtD
Midazolam—GABRB1—Transmembrane transport of small molecules—CARM1—psoriasis	7.53e-05	0.00155	CbGpPWpGaD
Midazolam—GABRA6—Transmembrane transport of small molecules—CP—psoriasis	7.47e-05	0.00154	CbGpPWpGaD
Midazolam—ABCB1—Allograft Rejection—IL4—psoriasis	7.44e-05	0.00154	CbGpPWpGaD
Midazolam—GABRA4—Transmembrane transport of small molecules—CP—psoriasis	7.37e-05	0.00152	CbGpPWpGaD
Midazolam—CYP4B1—Metabolism—CARM1—psoriasis	7.33e-05	0.00151	CbGpPWpGaD
Midazolam—ABCB1—Allograft Rejection—HLA-B—psoriasis	7.27e-05	0.0015	CbGpPWpGaD
Midazolam—ABCB1—HIF-1-alpha transcription factor network—LEP—psoriasis	7.27e-05	0.0015	CbGpPWpGaD
Midazolam—Dizziness—Methotrexate—psoriasis	7.14e-05	0.000227	CcSEcCtD
Midazolam—GABRA6—Transmembrane transport of small molecules—CARM1—psoriasis	7.12e-05	0.00147	CbGpPWpGaD
Midazolam—GABRA4—Transmembrane transport of small molecules—CARM1—psoriasis	7.03e-05	0.00145	CbGpPWpGaD
Midazolam—Vomiting—Methotrexate—psoriasis	6.87e-05	0.000218	CcSEcCtD
Midazolam—CYP4B1—Metabolism of lipids and lipoproteins—PPARG—psoriasis	6.85e-05	0.00141	CbGpPWpGaD
Midazolam—Rash—Methotrexate—psoriasis	6.81e-05	0.000216	CcSEcCtD
Midazolam—Dermatitis—Methotrexate—psoriasis	6.8e-05	0.000216	CcSEcCtD
Midazolam—ABCB1—HIF-1-alpha transcription factor network—NOS2—psoriasis	6.77e-05	0.0014	CbGpPWpGaD
Midazolam—Headache—Methotrexate—psoriasis	6.77e-05	0.000215	CcSEcCtD
Midazolam—GABRB2—Transmembrane transport of small molecules—CP—psoriasis	6.74e-05	0.00139	CbGpPWpGaD
Midazolam—ABCB1—Allograft Rejection—HLA-A—psoriasis	6.74e-05	0.00139	CbGpPWpGaD
Midazolam—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—psoriasis	6.63e-05	0.00137	CbGpPWpGaD
Midazolam—GABRA5—Transmembrane transport of small molecules—CP—psoriasis	6.55e-05	0.00135	CbGpPWpGaD
Midazolam—GABRA3—Transmembrane transport of small molecules—CP—psoriasis	6.43e-05	0.00133	CbGpPWpGaD
Midazolam—GABRB2—Transmembrane transport of small molecules—CARM1—psoriasis	6.43e-05	0.00133	CbGpPWpGaD
Midazolam—Nausea—Methotrexate—psoriasis	6.41e-05	0.000204	CcSEcCtD
Midazolam—GABRA2—Transmembrane transport of small molecules—CP—psoriasis	6.32e-05	0.00131	CbGpPWpGaD
Midazolam—GABRB3—Transmembrane transport of small molecules—CP—psoriasis	6.28e-05	0.0013	CbGpPWpGaD
Midazolam—GABRA5—Transmembrane transport of small molecules—CARM1—psoriasis	6.25e-05	0.00129	CbGpPWpGaD
Midazolam—GABRG2—Transmembrane transport of small molecules—CP—psoriasis	6.17e-05	0.00127	CbGpPWpGaD
Midazolam—ABCB1—Allograft Rejection—HLA-DRB1—psoriasis	6.16e-05	0.00127	CbGpPWpGaD
Midazolam—GABRA3—Transmembrane transport of small molecules—CARM1—psoriasis	6.14e-05	0.00127	CbGpPWpGaD
Midazolam—GABRA2—Transmembrane transport of small molecules—CARM1—psoriasis	6.03e-05	0.00124	CbGpPWpGaD
Midazolam—GABRB3—Transmembrane transport of small molecules—CARM1—psoriasis	5.99e-05	0.00124	CbGpPWpGaD
Midazolam—GABRG2—Transmembrane transport of small molecules—CARM1—psoriasis	5.88e-05	0.00121	CbGpPWpGaD
Midazolam—GABRB3—BDNF signaling pathway—JUN—psoriasis	5.59e-05	0.00115	CbGpPWpGaD
Midazolam—GABRA1—Transmembrane transport of small molecules—CP—psoriasis	5.39e-05	0.00111	CbGpPWpGaD
Midazolam—GABRB3—BDNF signaling pathway—NFKB1—psoriasis	5.38e-05	0.00111	CbGpPWpGaD
Midazolam—CYP3A7—Metabolism—NDUFA5—psoriasis	5.33e-05	0.0011	CbGpPWpGaD
Midazolam—GABRA1—Transmembrane transport of small molecules—CARM1—psoriasis	5.14e-05	0.00106	CbGpPWpGaD
Midazolam—SLC22A1—Metabolism—NDUFA5—psoriasis	4.96e-05	0.00102	CbGpPWpGaD
Midazolam—GABRA1—SIDS Susceptibility Pathways—CXCL8—psoriasis	4.84e-05	0.000998	CbGpPWpGaD
Midazolam—GABRB3—BDNF signaling pathway—STAT3—psoriasis	4.83e-05	0.000997	CbGpPWpGaD
Midazolam—SLC22A1—Transmembrane transport of small molecules—CP—psoriasis	4.61e-05	0.000952	CbGpPWpGaD
Midazolam—UGT1A4—Metabolism—CARM1—psoriasis	4.59e-05	0.000947	CbGpPWpGaD
Midazolam—CYP3A7—Metabolism—CYP2S1—psoriasis	4.54e-05	0.000936	CbGpPWpGaD
Midazolam—CYP4B1—Metabolism—CAT—psoriasis	4.51e-05	0.000931	CbGpPWpGaD
Midazolam—ABCB1—Allograft Rejection—IFNG—psoriasis	4.5e-05	0.000928	CbGpPWpGaD
Midazolam—GABRA1—SIDS Susceptibility Pathways—JUN—psoriasis	4.5e-05	0.000928	CbGpPWpGaD
Midazolam—ABCB1—HIF-1-alpha transcription factor network—JUN—psoriasis	4.49e-05	0.000926	CbGpPWpGaD
Midazolam—SLC22A1—Transmembrane transport of small molecules—CARM1—psoriasis	4.4e-05	0.000908	CbGpPWpGaD
Midazolam—GABRA1—SIDS Susceptibility Pathways—NFKB1—psoriasis	4.33e-05	0.000893	CbGpPWpGaD
Midazolam—SLC22A1—Metabolism—CYP2S1—psoriasis	4.22e-05	0.000871	CbGpPWpGaD
Midazolam—ABCB1—Allograft Rejection—CXCL8—psoriasis	4.18e-05	0.000863	CbGpPWpGaD
Midazolam—CYP2B6—Metabolism—NDUFA5—psoriasis	3.94e-05	0.000814	CbGpPWpGaD
Midazolam—GABRA1—SIDS Susceptibility Pathways—VEGFA—psoriasis	3.93e-05	0.000811	CbGpPWpGaD
Midazolam—ABCB1—HIF-1-alpha transcription factor network—VEGFA—psoriasis	3.92e-05	0.000809	CbGpPWpGaD
Midazolam—CYP2E1—Metabolism—NDUFA5—psoriasis	3.86e-05	0.000798	CbGpPWpGaD
Midazolam—CYP3A5—Metabolism—NDUFA5—psoriasis	3.86e-05	0.000796	CbGpPWpGaD
Midazolam—CYP4B1—Metabolism—APOE—psoriasis	3.5e-05	0.000723	CbGpPWpGaD
Midazolam—ABCB1—Integrated Pancreatic Cancer Pathway—PCNA—psoriasis	3.44e-05	0.000711	CbGpPWpGaD
Midazolam—ABCB1—Allograft Rejection—VEGFA—psoriasis	3.4e-05	0.000701	CbGpPWpGaD
Midazolam—GABRA1—SIDS Susceptibility Pathways—TNF—psoriasis	3.37e-05	0.000695	CbGpPWpGaD
Midazolam—CYP2B6—Metabolism—CYP2S1—psoriasis	3.35e-05	0.000692	CbGpPWpGaD
Midazolam—CYP2E1—Metabolism—CYP2S1—psoriasis	3.29e-05	0.000678	CbGpPWpGaD
Midazolam—CYP3A5—Metabolism—CYP2S1—psoriasis	3.28e-05	0.000677	CbGpPWpGaD
Midazolam—CYP4B1—Metabolism—PPARG—psoriasis	3.05e-05	0.00063	CbGpPWpGaD
Midazolam—ABCB1—Allograft Rejection—TNF—psoriasis	2.91e-05	0.000601	CbGpPWpGaD
Midazolam—ABCB1—Metabolism—NDUFA5—psoriasis	2.91e-05	0.000601	CbGpPWpGaD
Midazolam—ABCB1—Integrated Pancreatic Cancer Pathway—NFKBIA—psoriasis	2.89e-05	0.000597	CbGpPWpGaD
Midazolam—UGT1A4—Metabolism—CAT—psoriasis	2.82e-05	0.000582	CbGpPWpGaD
Midazolam—GABRA1—SIDS Susceptibility Pathways—IL6—psoriasis	2.72e-05	0.000561	CbGpPWpGaD
Midazolam—ABCB1—Transmembrane transport of small molecules—CP—psoriasis	2.7e-05	0.000558	CbGpPWpGaD
Midazolam—ABCB1—Transmembrane transport of small molecules—CARM1—psoriasis	2.58e-05	0.000532	CbGpPWpGaD
Midazolam—ABCB1—Metabolism—CYP2S1—psoriasis	2.47e-05	0.000511	CbGpPWpGaD
Midazolam—CYP3A7—Metabolism—CARM1—psoriasis	2.22e-05	0.000457	CbGpPWpGaD
Midazolam—UGT1A4—Metabolism—APOE—psoriasis	2.19e-05	0.000452	CbGpPWpGaD
Midazolam—SLC22A1—Metabolism—CARM1—psoriasis	2.06e-05	0.000425	CbGpPWpGaD
Midazolam—ABCB1—Integrated Pancreatic Cancer Pathway—JUN—psoriasis	1.92e-05	0.000396	CbGpPWpGaD
Midazolam—UGT1A4—Metabolism—PPARG—psoriasis	1.91e-05	0.000394	CbGpPWpGaD
Midazolam—ABCB1—Integrated Pancreatic Cancer Pathway—NFKB1—psoriasis	1.85e-05	0.000381	CbGpPWpGaD
Midazolam—CYP3A4—Metabolism—NDUFA5—psoriasis	1.79e-05	0.00037	CbGpPWpGaD
Midazolam—ABCB1—Integrated Pancreatic Cancer Pathway—VEGFA—psoriasis	1.68e-05	0.000346	CbGpPWpGaD
Midazolam—CYP2B6—Metabolism—CARM1—psoriasis	1.64e-05	0.000338	CbGpPWpGaD
Midazolam—CYP2E1—Metabolism—CARM1—psoriasis	1.6e-05	0.000331	CbGpPWpGaD
Midazolam—CYP3A5—Metabolism—CARM1—psoriasis	1.6e-05	0.00033	CbGpPWpGaD
Midazolam—CYP3A4—Metabolism—CYP2S1—psoriasis	1.52e-05	0.000315	CbGpPWpGaD
Midazolam—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—psoriasis	1.44e-05	0.000296	CbGpPWpGaD
Midazolam—CYP3A7—Metabolism—CAT—psoriasis	1.36e-05	0.000281	CbGpPWpGaD
Midazolam—SLC22A1—Metabolism—CAT—psoriasis	1.27e-05	0.000262	CbGpPWpGaD
Midazolam—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—psoriasis	1.27e-05	0.000261	CbGpPWpGaD
Midazolam—ABCB1—Metabolism—CARM1—psoriasis	1.21e-05	0.000249	CbGpPWpGaD
Midazolam—CYP3A7—Metabolism—APOE—psoriasis	1.06e-05	0.000219	CbGpPWpGaD
Midazolam—CYP2B6—Metabolism—CAT—psoriasis	1.01e-05	0.000208	CbGpPWpGaD
Midazolam—CYP2E1—Metabolism—CAT—psoriasis	9.87e-06	0.000204	CbGpPWpGaD
Midazolam—SLC22A1—Metabolism—APOE—psoriasis	9.85e-06	0.000203	CbGpPWpGaD
Midazolam—CYP3A5—Metabolism—CAT—psoriasis	9.85e-06	0.000203	CbGpPWpGaD
Midazolam—CYP3A7—Metabolism—PPARG—psoriasis	9.22e-06	0.00019	CbGpPWpGaD
Midazolam—SLC22A1—Metabolism—PPARG—psoriasis	8.58e-06	0.000177	CbGpPWpGaD
Midazolam—CYP2B6—Metabolism—APOE—psoriasis	7.83e-06	0.000162	CbGpPWpGaD
Midazolam—CYP2E1—Metabolism—APOE—psoriasis	7.67e-06	0.000158	CbGpPWpGaD
Midazolam—CYP3A5—Metabolism—APOE—psoriasis	7.65e-06	0.000158	CbGpPWpGaD
Midazolam—CYP3A4—Metabolism—CARM1—psoriasis	7.44e-06	0.000154	CbGpPWpGaD
Midazolam—ABCB1—Metabolism—CAT—psoriasis	7.43e-06	0.000153	CbGpPWpGaD
Midazolam—CYP2B6—Metabolism—PPARG—psoriasis	6.82e-06	0.000141	CbGpPWpGaD
Midazolam—CYP2E1—Metabolism—PPARG—psoriasis	6.68e-06	0.000138	CbGpPWpGaD
Midazolam—CYP3A5—Metabolism—PPARG—psoriasis	6.67e-06	0.000138	CbGpPWpGaD
Midazolam—ABCB1—Metabolism—APOE—psoriasis	5.77e-06	0.000119	CbGpPWpGaD
Midazolam—ABCB1—Metabolism—PPARG—psoriasis	5.03e-06	0.000104	CbGpPWpGaD
Midazolam—CYP3A4—Metabolism—CAT—psoriasis	4.58e-06	9.45e-05	CbGpPWpGaD
Midazolam—CYP3A4—Metabolism—APOE—psoriasis	3.56e-06	7.34e-05	CbGpPWpGaD
Midazolam—CYP3A4—Metabolism—PPARG—psoriasis	3.1e-06	6.4e-05	CbGpPWpGaD
